癌症免疫疗法市场规模、份额、成长分析（按产品类型、应用、形式、最终用户、分销管道和地区）—2025 年至 2032 年行业预测

癌症免疫治疗市场规模预计将在 2023 年达到 1364 亿美元，从 2024 年的 1486.8 亿美元增长到 2032 年的 2962.5 亿美元，在预测期内（2025-2032 年）的复合年增长率为 9.0%。

由于医疗支出增加、癌症发病率上升、医疗保险覆盖率改善以及治疗技术进步等因素，全球癌症免疫治疗市场预计将经历显着增长。免疫疗法增强了免疫系统对抗多种癌症（从黑色素瘤到肺癌）的能力，其副作用比传统治疗方法更少，并提供长期保护。根据美国癌症研究所的统计，2020年美国将新增超过180万例癌症病例，凸显了寻找有效治疗方法的迫切性。然而，由于严格的法律规范和高昂的开发成本，市场可能面临挑战，这可能会限制新进入者并在预测期内减缓该行业的整体进展。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 二次资料和一次资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分机会分析

市场动态与展望

• 市场概览
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

关键市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024年）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 监管分析

癌症免疫疗法市场规模（按产品类型和复合年增长率） (2025-2032)

• 市场概览
• 查核点抑制剂
• 单株抗体
• 疫苗
• 细胞疗法
• 免疫调节药物
• 溶瘤病毒

癌症免疫治疗市场规模（依应用）及复合年增长率（2025-2032）

• 市场概览
• 肺癌
• 乳癌
• 黑色素瘤
• 多发性骨髓瘤
• 摄护腺癌
• 卵巢癌
• 子宫颈癌
• 胃癌
• 大肠直肠癌
• 头颈癌
• 其他的

癌症免疫疗法市场规模（按类型及复合年增长率）（2025-2032）

• 市场概览
• 静脉注射（IV）
• 肌肉注射
• 口服

癌症免疫治疗市场规模（按最终用户和复合年增长率） (2025-2032)

• 市场概览
• 医院
• 肿瘤诊所
• 居家照护
• 其他的

癌症免疫治疗市场规模（依分销管道划分）及复合年增长率（2025-2032）

• 市场概览
• 直销
• 零售
• 药局

癌症免疫治疗市场规模（按地区）及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市场占有率分析（2024年）
• 主要企业简介
  • 公司详情
  • 产品系列分析
  • 公司分部份额分析
  • 收益与前一年同期比较对比（2022-2024 年）

主要企业简介

• Roche Holding AG（Switzerland）
• Merck & Co., Inc.（USA）
• Bristol Myers Squibb Company（USA）
• AstraZeneca plc（UK）
• Johnson & Johnson（USA）
• Novartis International AG（Switzerland）
• Pfizer Inc.（USA）
• Amgen Inc.（USA）
• Eli Lilly and Company（USA）
• Gilead Sciences, Inc.（USA）
• Sanofi（France）
• Regeneron Pharmaceuticals Inc.（USA）
• Bayer AG（Germany）
• Takeda Pharmaceutical Company Limited（Japan）
• GlaxoSmithKline plc（UK）
• Daiichi Sankyo Company, Limited（Japan）
• Incyte Corporation（USA）

结论和建议

Cancer Immunotherapy Market size was valued at USD 136.4 billion in 2023 and is poised to grow from USD 148.68 billion in 2024 to USD 296.25 billion by 2032, growing at a CAGR of 9.0% during the forecast period (2025-2032).

The global cancer immunotherapy market is poised for significant growth, driven by factors such as increasing healthcare expenditures, rising cancer incidence, improved access to medical insurance, and advancements in treatment technologies. Immunotherapy, which enhances the immune system's ability to combat various cancers-ranging from melanoma to lung cancer-offers long-lasting protection with fewer side effects compared to traditional treatments. Statistics from the National Cancer Institute highlighted that over 1.8 million new cancer cases were diagnosed in the U.S. in 2020, emphasizing the urgent need for effective therapies. However, the market may face challenges due to stringent regulatory frameworks and high development costs, potentially restricting new entrants and slowing overall progress in the sector during the forecast period.

Top-down and bottom-up approaches were used to estimate and validate the size of the Cancer Immunotherapy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Cancer Immunotherapy Market Segments Analysis

Global Cancer Immunotherapy Market is segmented by Product Type, Application, Form, End User, Distribution Channel and region. Based on Product Type, the market is segmented into Checkpoint Inhibitors, Monoclonal Antibodies, Vaccines, Cell Therapies, Immunomodulators and Oncolytic Virus. Based on Application, the market is segmented into Lung Cancer,Breast Cancer, Melanoma, Multiple Myeloma, Prostate Cancer, Ovarian Cancer, Cervical Cancer, Stomach Cancer, Colorectal Cancer, Head & Neck Cancer and Others. Based on Form, the market is segmented into Intravenous (IV), Intramuscular and Oral. Based on End User, the market is segmented into Hospitals, Oncology Clinics, Homecare and Others. Based on Distribution Channel, the market is segmented into Direct Tenders, Retail Sales and Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Cancer Immunotherapy Market

The global cancer immunotherapy market is experiencing significant growth, largely driven by the increasing incidence of various types of cancer around the world. The rising rates of conditions such as lung, breast, colorectal, melanoma, and hematological cancers underscore the urgent need for innovative and effective treatment options. As cancer continues to be one of the leading causes of morbidity and mortality globally, the demand for advanced therapeutic solutions is critical. This scenario emphasizes the importance of creating novel strategies that can effectively tackle the escalating challenges posed by cancer, thereby enhancing patient outcomes and overall public health.

Restraints in the Cancer Immunotherapy Market

The cancer immunotherapy market faces significant challenges that hinder its growth. Over the past decade, the rising incidence of cancer has spurred extensive research and development in the field of cancer treatments. However, as the processes of manufacturing and testing immunotherapies become more elaborate, the associated costs for patients have skyrocketed, ultimately limiting market expansion. Additionally, the potential side effects related to immunotherapy-such as swelling, skin rashes, heart palpitations, and other adverse reactions-can deter patients from pursuing these treatments. Consequently, these factors contribute to the constraints affecting the overall growth of the cancer immunotherapy market.

Market Trends of the Cancer Immunotherapy Market

The Cancer Immunotherapy market is experiencing a dynamic shift towards diversified immunotherapy solutions, driven by an increasing global cancer patient population and accelerated advancements in medical research. Recent innovations, such as the novel method developed by researchers at the University of Texas and MD Anderson Cancer Center for extracting immunotherapy drugs through peptide linkages within the human body, signify a critical evolution in drug development. This approach not only enhances the efficacy of treatments but also opens new avenues for personalized cancer therapies, making it a promising trend that is likely to attract significant investment and foster competitive growth within the sector.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Regulatory Analysis

Global Cancer Immunotherapy Market Size by Product Type & CAGR (2025-2032)

• Market Overview
• Checkpoint Inhibitors
• Monoclonal Antibodies
• Vaccines
• Cell Therapies
• Immunomodulators
• Oncolytic Virus

Global Cancer Immunotherapy Market Size by Application & CAGR (2025-2032)

• Market Overview
• Lung Cancer
• Breast Cancer
• Melanoma
• Multiple Myeloma
• Prostate Cancer
• Ovarian Cancer
• Cervical Cancer
• Stomach Cancer
• Colorectal Cancer
• Head & Neck Cancer
• Others

Global Cancer Immunotherapy Market Size by Form & CAGR (2025-2032)

• Market Overview
• Intravenous (IV)
• Intramuscular
• Oral

Global Cancer Immunotherapy Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospitals
• Oncology Clinics
• Homecare
• Others

Global Cancer Immunotherapy Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Direct Tenders
• Retail Sales
• Pharmacies

Global Cancer Immunotherapy Market Size & CAGR (2025-2032)

• North America (Product Type, Application, Form, End User, Distribution Channel)
  • US
  • Canada
• Europe (Product Type, Application, Form, End User, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product Type, Application, Form, End User, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product Type, Application, Form, End User, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product Type, Application, Form, End User, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Roche Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis International AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Daiichi Sankyo Company, Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Incyte Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations